Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 22, Issue 9, 2015, Pages 754-762

  Han, G R ^a   Jiang, H X ^a   Yue, X ^a   Ding, Y ^b   Wang, C M ^a   Wang, G J ^a   Yang, Y F ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

HBV infection; pregnancy; telbivudine; vertical transmission

Indexed keywords

HEPATITIS B(E) ANTIGEN; PLACEBO; TELBIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; THYMIDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE DOSAGE; HEPATITIS B; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; NONHUMAN; PERINATAL CARE; PERINATAL INFECTION; PREGNANCY; PRIORITY JOURNAL; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; BLOOD; CHINA; INFANT; LONGITUDINAL STUDY; MALE; NEWBORN; PREVENTION AND CONTROL; PROSPECTIVE STUDY; TRANSMISSION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHINA; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; MALE; PREGNANCY; PROSPECTIVE STUDIES; THYMIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936845819     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12379     Document Type: Article

References (27)

1. Jonas MM,. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009; 29 (Suppl. 1): 133-139.
2. Lavanchy D,. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 (Suppl. 1): S1-S3.
3. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP,. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170 (6): 1418-1423.
4. del Canho R, Grosheide PM, Mazel JA, et al,. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15 (15): 1624-1630.
5. Wiseman E, Fraser MA, Holden S, et al,. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190 (9): 489-492.
6. Zou H, Chen Y, Duan Z, Zhang H, Pan C,. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19 (2): e18-e25.
7. Pan CQ, Duan ZP, Bhamidimarri KR, et al,. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012; 10 (5): 452-459.
8. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 (3): 263-283.
9. Keeffe EB, Dieterich DT, Han SH, et al,. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6 (12): 1315-1341.
10. Han GR, Cao MK, Zhao W, et al,. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55 (6): 1215-1221.
11. Zhang LJ, Wang L,. [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 2009; 17 (8): 561-563.
12. Petersen J,. HBV treatment and pregnancy. J Hepatol 2011; 55 (6): 1171-1173.
13. Li AZ, Xiao XM,. Study of the clinical diagnostic criteria of intrauterine Hepatitis B Virus infection. J Matern Child Healthc China 2007; 22 (4): 475-477.
14. WHO. Hepatitis B factsheet No 204. World Health Organization; 2013. Report No.: 204.
15. Bzowej NH,. Optimal management of the Hepatitis B Patient who desires pregnancy or is pregnant. Curr Hepat Rep 2012; 11 (2): 82-89.
16. Soleimani Amiri MJ, Hasanjani Roushan MR, Baiany M, Taheri H, Hasanjani RM,. Outcomes of passive-active immunoprophylaxis given to infants of mothers infected with hepatitis B virus in Babol, Iran. J Clin Virol 2010; 49 (4): 283-285.
17. Godbole G, Irish D, Basarab M, et al,. Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals. BMC Pregnancy Childbirth 2013; 13: 222.
18. Guo S, Zhao F, Wu K, et al,. Trends of caesarean section and related social and demographic factors in China from 1971 to 2003. ChinJ Perinatal Med 2005; 8: 145-149.
19. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG,. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998; 27 (1): 100-106.
20. Dienstag J, Easley C, Kirkpatrick P,. Telbivudine. Nat Rev Drug Discov 2007; 6 (4): 267-268.
21. Ruiz-Sancho A, Sheldon J, Soriano V,. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 2007; 7 (5): 751-761.
22. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2013. Registry Coordinating Center, Wilmington, NC, USA; 2013.
23. Beasley RP,. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009; 19 (4): 231-234.
24. Resuli B, Prifti S, Kraja B, Nurka T, Basho M, Sadiku E,. Epidemiology of hepatitis B virus infection in Albania. World J Gastroenterol 2009; 15 (7): 849-852.
25. Yunxia Z, Hua Z, Huaibin Z,. The impact of abnormal ALT on the outcome of HBsAg positive pregnant women. Shangdong Medicine 2010; 50 (32): 3-4.
26. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, et al,. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136 (2): 486-495.
27. Chu CJ,. Management of chronic hepatitis B-case interactive challenges. J Chin Med Assoc 2007; 70 (Supplement): 99-100.